Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Court Place Advisors LLC

Court Place Advisors LLC cut its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 4.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,850 shares of the medical equipment provider’s stock after selling 260 shares during the period. Court Place Advisors LLC’s holdings in Intuitive Surgical were worth $1,974,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Portside Wealth Group LLC boosted its holdings in shares of Intuitive Surgical by 8.2% in the 4th quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after buying an additional 62 shares during the period. Sequoia Financial Advisors LLC boosted its stake in Intuitive Surgical by 58.0% during the 4th quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after purchasing an additional 3,054 shares during the period. Kades & Cheifetz LLC acquired a new position in Intuitive Surgical during the 4th quarter valued at about $230,000. Blair William & Co. IL boosted its stake in Intuitive Surgical by 3.1% during the 3rd quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after purchasing an additional 11,400 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in Intuitive Surgical by 21.2% during the 3rd quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after purchasing an additional 129,194 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Robert Desantis sold 20,296 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the transaction, the executive vice president now directly owns 5,507 shares of the company’s stock, valued at $2,168,656.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, EVP Myriam Curet sold 4,318 shares of the company’s stock in a transaction on Friday, January 26th. The shares were sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the completion of the transaction, the executive vice president now directly owns 189 shares in the company, valued at approximately $69,958.35. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Robert Desantis sold 20,296 shares of the stock in a transaction on Friday, March 8th. The shares were sold at an average price of $393.80, for a total transaction of $7,992,564.80. Following the completion of the transaction, the executive vice president now owns 5,507 shares of the company’s stock, valued at approximately $2,168,656.60. The disclosure for this sale can be found here. Insiders have sold 248,418 shares of company stock worth $95,927,097 over the last 90 days. 0.80% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on ISRG shares. Wells Fargo & Company boosted their target price on shares of Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Truist Financial boosted their target price on shares of Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Barclays upped their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a research note on Thursday, January 25th. Stifel Nicolaus upped their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Finally, Raymond James upped their price target on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research note on Thursday, January 25th. Five analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $375.70.

Intuitive Surgical Stock Down 1.2 %

Shares of ISRG stock traded down $4.38 during trading hours on Wednesday, reaching $374.17. 1,625,510 shares of the stock traded hands, compared to its average volume of 1,635,915. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The business has a fifty day moving average price of $387.90 and a 200 day moving average price of $342.17. The firm has a market capitalization of $132.62 billion, a PE ratio of 75.01, a PEG ratio of 5.86 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The business had revenue of $1.93 billion for the quarter, compared to analyst estimates of $1.89 billion. During the same quarter in the previous year, the business earned $0.91 earnings per share. The firm’s revenue was up 16.6% compared to the same quarter last year. Research analysts expect that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.